Using Biomarkers to Optimize Antibiotic Strategies in Sepsis
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 145 people enrolled
- Started
- Jan 2012
- Ended
- Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Biomarker Algorithm Intervention
- Record updated
- 5 January 2024
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- SIRS Criteria; SIRS is considered to be present when patients have more than one of the following clinical findings:; body temperature >38°C or <36°C; heart rate >90 min-1; respiratory rate of >20 min-1 or a Paco2 of <32 mm Hg; and a white blood cell count of >12,000 cells µL-1 or <4,000 µL-1
- new empiric antibiotic therapy is initiated, indicating the suspicion of infection. Accepted criteria for SIRS will be used for the Medical Intensive Care Unit and Surgical Intensive Care Unit populations, with appropriate age-specific vital signs definitions to help make the definitions relevant for the Pediatric Intensive Care Unit population
Who cannot take part
- absence of initiation or expansion of antibiotic therapy despite meeting criteria for sepsis
- active chemotherapy within the 3 months preceding eligibility or
- presence of an immunocompromising condition; An immunocompromising condition will be defined as one of the following:
- diagnosis of cystic fibrosis; These criteria all represent conditions in which antibiotic use is much less likely to be decreased regardless of the results of a biomarker and are consistent with exclusion criteria used in past studies of the impact of biomarkers
- human immunodeficiency virus (HIV) infection with a t-helper cell (CD4) count <200 cell/mm3; 2) immunosuppressive therapy after organ transplantation
- neutropenia (<500 neutrophils/mm3)
- a code status of "do not resuscitate"
Where in United States
- Hospital of the University of Pennsylvania - Medical Intensive Care UnitPhiladelphia, United States
About the trial
What the trial wants to find out
The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the results of this work will be critical in informing future strategies to eliminate unnecessary antibiotic use and curb the continued rise in antimicrobial resistance.
The 2 groups in the trial
- ObservationalNo study treatment, for comparison
9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.
- Biomarker Algorithm InterventionTreatment being tested
The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics. The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network - Randomized Control Trial
- Record updated
- 5 January 2024